Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments
I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target
No preference
FRalpha (Folate receptor 1)
No preference

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT04300556I/IIPlatinum resistant ovarian cancerA Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor TypesAR, FL, GA, NJ, NY, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MORAb-202Farletuzumab ecteribulinADC: anti-FOLR1 + microtubule destabilizer (eribulin)Clinical Trials
NCT05001282I/IIAdvanced solid tumorsDose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing TumorsAZ, FL, MN, NY, NC, TN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ELU001ADC: Folic Acid analogs + topoisomerase I inhibitor (exatecan)Clinical Trials
NCT05483933IPlatinum resistant ovarian cancer with prior bevacizumab, at most 1 prior therapy for platinum resistant disease; for combination with mirvetuximab patients must be high grade serous, FRalpha+ (inc expansion)An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered With Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects With Platinum-Resistant Ovarian CancersCA, MIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
Mirvetuximab soravtansineM9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid ConjugateADC: anti-FOLR1 + microtubule destabilizer (DM4)Clinical Trials
SL-172154Blocks CD47 signaling and stimulates CD40 to increase/activate antigen-presenting cells, stimulate tumor cell phagocytosis and immune responseClinical Trials
NCT05200364IRecurrent high grade serous ovarian cancer (inc expansion)A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)FL, PA, TN, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BevacizumabAvastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chainVEGF antagonistApproved in Ovarian Cancer
STRO-002ADC: anti-FOLR1 + microtubule destabilizer (SC209)Clinical Trials

If you have any questions or would like help with your search, please call us at: 858-657-0282 or email us at